Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma

The goal of this clinical trial is to learn about radiofrequency ablation in patients with unresectable bile duct cancer who receive systemic chemotherapy and bile duct stenting. The main questions it aims to answer are: * Does radiofrequency ablation of tumorous bile duct occlusion reduce risk of complications in these patients (eg stent dysfunction, delay of chemotherapy, infections etc)? * Is radiofrequency ablation safe in these patients? All participants will receive standard treatment with systemic chemotherapy and bile duct stenting. Researchers will compare two groups (one group will receive additional radiofrequency ablation, the other not).

NCT Number	NCT06175845
Lead Sponsor	Universitätsklinikum Hamburg-Eppendorf
Conditions	Cholangiocarcinoma, Klatskin Tumor, Bile Duct Cancer, Liver Cancer
Enrollment	130 participants
Start Date	2024-02
Primary Completion	2026-01 (estimated)
Study Completion	2026-07 (estimated)
Updated on ClinicalTrials.gov	2023-12-19